Table 3.
Demographics and clinical characteristics of patients with ICI-related MG and those with idiopathic MGa
| Variable | ICI-related MG | iMG [26, 28–30, 32, 50] |
|---|---|---|
| Mean age (years) | 71 ± 9.7 | 60.0 ± 18.8 |
| Female gender (%) | 35% | 59% |
| MGFA classification | ||
| I | 12% | 52% |
| II | 22% | 43% |
| III | 12% | 3% |
| IV | 6% | 2% |
| V | 45% | 0% |
| Time from first symptom to Class IV/V | 1–60 days (Median: 7 days) | 2–3 years |
| Overlap with myositis/myocarditis | 42% | 0.9% |
| Antibodies | ||
| Anti-AChR | 66% | 83.2% |
| Anti-striated muscle | 67% | 36%b |
| Anti-MuSK | 3% | 2.3% |
aAbbreviations: ICI immune checkpoint inhibitors, MG myasthenia gravis, iMG, idiopathic myasthenia gravis, MGFA myasthenia gravis foundation of America, Anti-AChR Anti-Acetylcholine receptor, Anti-MuSK Anti-muscle specific kinase. Numbers are rounded to the nearest whole number
bFor patients with non-thymomatous MG